Physician profile
Brian H Wetchler
NPI 1710253158
$1,743.27
in general payments reported to CMS, 2019-2025
24 companies · $76.70 in 2025
The $76.70 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $193 · 2021: $335 · 2022: $289 · 2023: $233 · 2024: $148 · 2025: $76.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $224.32 | 2021-2022 | |
| Amgen INC. | $193.05 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $137.18 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $132.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $115.78 | 2019-2022 | |
| Allergan, INC. | $96.05 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $91.60 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $91.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $90.60 | 2019-2024 | Airsupra |
| Sanofi-Aventis U.S. LLC | $83.85 | 2019 | |
| Amarin Pharma, INC. | $71.11 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $66.51 | 2019-2023 | |
| Astellas Pharma US INC | $52.77 | 2023-2024 | Veozah |
| Sanofi Pasteur INC. | $47.09 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $38.16 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $31.04 | 2022-2023 | Seglentis, Livalo |
| Amneal Pharmaceuticals LLC | $22.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.59 | 2019 | |
| Glaxosmithkline, LLC. | $15.26 | 2023 | Shingrix, Arexvy |
| Heartflow, INC. | $14.21 | 2023 | Ffrct |
| Almatica Pharma LLC | $13.91 | 2023 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $12.58 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wetchler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.